Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis.
essential thrombocytosis
platelets
thrombocytapheresis
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
11
04
2018
revised:
08
11
2018
accepted:
19
12
2018
pubmed:
10
1
2019
medline:
16
1
2020
entrez:
10
1
2019
Statut:
ppublish
Résumé
Essential thrombocytosis (ET) is a chronic myeloproliferative neoplasm characterized by the presence of thrombocytosis and it can be complicated by thrombotic and/or hemorrhagic events. Treatment options include low-dose aspirin and cytoreductive agents such as hydroxyurea. In cases of extreme thrombocytosis, therapeutic thrombocytapheresis can be a useful procedure. We present a case of a 61-year-old-man previously diagnosed with CALR-mutated ET, who develop acute myeloid leukemia. When recovering after induction chemotherapy, he developed an extreme thrombocytosis up to 2337 × 10
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-506Informations de copyright
© 2019 Wiley Periodicals, Inc.